LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

Home・Aktien・Krystal Biotech Inc

Krystal Biotech Inc

Open

BrancheGesundheitswesen

312.38 3.92

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

299.18

Max

313.43

Schlüsselkennzahlen
By Trading Economics
Einkommen	4.5M 56M
Verkäufe	9.3M 116M
KGV Branchendurchschnitt	40.057 50.102
EPS	1.83
Gewinnspanne	48.069
Angestellte	295
EBITDA	16M 55M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+5.01% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	816M 8.8B
Vorheriger Eröffnungskurs	308.46
Vorheriger Schlusskurs	312.38

Nachrichtenstimmung

By Acuity

50%

156 / 344 Ranking in Healthcare

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Mai 2026, 22:47 UTC

Ergebnisse

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28. Mai 2026, 20:45 UTC

Ergebnisse

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28. Mai 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28. Mai 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28. Mai 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28. Mai 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28. Mai 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28. Mai 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. Mai 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28. Mai 2026, 22:37 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

M&A-Related Insurance Payments In North America Rise -- Market Talk

28. Mai 2026, 22:04 UTC

Akquisitionen, Fusionen, Übernahmen

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28. Mai 2026, 22:04 UTC

Akquisitionen, Fusionen, Übernahmen

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28. Mai 2026, 21:12 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28. Mai 2026, 21:00 UTC

Ergebnisse

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28. Mai 2026, 20:57 UTC

Ergebnisse

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. Mai 2026, 20:55 UTC

Ergebnisse

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28. Mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28. Mai 2026, 20:48 UTC

Heiße Aktien

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28. Mai 2026, 20:34 UTC

Ergebnisse

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28. Mai 2026, 20:31 UTC

Ergebnisse

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28. Mai 2026, 20:28 UTC

Ergebnisse

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28. Mai 2026, 20:26 UTC

Ergebnisse

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. Mai 2026, 20:20 UTC

Ergebnisse

Costco 3Q Membership Fees $1.37B

28. Mai 2026, 20:20 UTC

Ergebnisse

Costco 3Q Net Sales $69.15B

28. Mai 2026, 20:19 UTC

Ergebnisse

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28. Mai 2026, 20:19 UTC

Ergebnisse

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28. Mai 2026, 20:17 UTC

Ergebnisse

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28. Mai 2026, 20:17 UTC

Ergebnisse

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

5.01% Vorteil

12-Monats-Prognose

Durchschnitt 322 USD 5.01%

Hoch 378 USD

Tief 284 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Krystal Biotech Inc – Dist abgegeben haben.

Stimmung

By Acuity

156 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.